enGene (ENGN) Holdings reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company’s common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price of the Company’s common shares on April 2, 2025, the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the employee’s employment commencement date and the remainder vesting in equal amounts monthly for three years thereafter, subject to the employee’s continued service as an employee of, or other service provider to, the Company through the applicable vesting dates.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Promising Outlook for enGene Holdings: Buy Rating Justified by Strong Clinical Progress and Financial Resilience
- Promising Trajectory and Strong Financial Position Justify Buy Rating for enGene Holdings
- Promising Prospects for enGene Holdings: Buy Rating on Detalimogene Voraplasmid’s Strong Clinical Profile
- enGene price target lowered to $34 from $37 at Morgan Stanley
- Lyft downgraded, Snowflake upgraded: Wall Street’s top analyst calls